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Abstract
Background: The serotonin type 3 receptor (5-HT3R) is a member of a superfamily of ligand
gated ion channels. All members of this family share a large degree of sequence homology and
presumably significant structural similarity. A large number of studies have explored the structure-
function relationships of members of this family, particularly the nicotinic and GABA receptors.
This information can be utilized to gain additional insights into specific structural and functional
features of other receptors in this family.
Results: Thirteen amino acids in the mouse 5-HT3ASR that correspond to the putative E binding
loop of the nicotinic α 7 receptor were chosen for mutagenesis. Due to the presence of a highly
conserved glycine in this region, it has been suggested that this binding loop is comprised of a
hairpin turn and may form a portion of the ligand-binding site in this ion channel family. Mutation
of the conserved glycine (G147) to alanine eliminated binding of the 5-HT3R antagonist
[3H]granisetron. Three tyrosine residues (Y140, Y142 and Y152) also significantly altered the
binding of 5-HT3R ligands. Mutations in neighboring residues had little or no effect on binding of
these ligands to the 5-HT3ASR.
Conclusion: Our data supports a role for the putative E-loop region of the 5-HT3R in the binding
of 5-HT, mCPBG, d-tc and lerisetron. 5-HT and mCPBG interact with Y142, d-tc with Y140 and
lerisetron with both Y142 and Y152. Our data also provides support for the hypothesis that this
region of the receptor is present in a loop structure.
Background
Sequence homology between the serotonin type 3 recep-
tor (5-HT3R), the nicotinic acetylcholine receptor
(nAChR), the GABAA receptor and the glycine receptor
suggests a large amount of structural similarity within this
superfamily of ligand gated ion channels[1–3]. This pre-
sumed structural homology can be used to guide site di-
rected mutagenesis studies of particular receptor subtypes.
On a gross level, all members of this superfamily assemble
as pentameric receptors [4]. In some cases, receptors can
be assembled from a single subunit (5-HT3AR and nico-
tinic α 7 receptors) [1,5–8]. In other cases, at least two dif-
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ferent subunits are required [2,4,9]. The ligand binding
site is thought to be formed at the junction between two
subunits [2,4].
Based on data obtained from affinity labeling and site di-
rected mutagenesis studies, several regions of the nicotinic
acetylcholine receptor have been implicated in ligand
binding [10]. Six essential loops appear to contribute to
the binding site with the position of each loop differing
slightly depending on whether the receptor is heteromeric
or homomeric[4]. For homomeric receptors such as the
α 7 nAChR, the loops are identified as A, B, C, D, E and F
[4,11]. The amino acids that interact with ligands presum-
ably extend into the binding site from these loops. Subu-
nits are composed of 2 faces (+ and -) with the + face of
one subunit forming one side of the binding site and the
– face of another subunit forming the complimentary
side. Some binding loops (A, B and C) are present on the
– face while the remaining loops (D and E) are present on
the + face. [4]. The individual amino acids that form bind-
ing interactions with the functional groups present on a
ligand are likely to differ for each receptor subtype, reflect-
ing the specificity of a particular binding site, however, the
overall structure of the binding domain may be similar
even for binding sites with different ligand specificities.
Identification of ligand specificity requires identification
of both the location or structure of individual binding site
loops and the amino acids present in a particular receptor
subtype.
The purpose of this study is to extend the information
available from other members of this receptor family to
the 5-HT3R. Sequence homology and a presumed struc-
tural similarity to other ligand gated ion channels suggests
that the E loop region of the 5-HT3AR forms part of the lig-
and binding domain for 5-HT3R ligands. This region ex-
tends from Y140 to K153 and is shown in Table 1. The
homologous sequences of other representative members
of this family are also shown. In the center of this region
is a critical glycine residue that is thought to play a role in
establishing a hairpin loop [12]. Recent x-ray crystallo-
graphic data obtained from an ACh binding protein
(AChBP) shows a loop structure in this region resulting
from a 3 residue turn containing a glycine homologous to
G147 of the 5-HT3R. On either side of this putative turn
region are residues that have been identified as important
to receptor binding [12–18]. The formation of this loop
structure brings amino acids on either side of glycine into
close proximity and may form a binding pocket that will
accommodate one or more functional groups. In order to
identify the interaction of amino acids in this binding
loop with 5-HT3R ligands, we have constructed alanine
mutations of residues throughout this region and evaluat-
ed the alteration in binding affinity of 5 different classes
of 5-HT3R ligands (Figure 1). Our data identifies 3 tyro-
sine residues that appear to interact selectively with each
structural class and supports the existence of a loop struc-
ture in this region of the receptor.
Results
All mutant receptors were tested for their ability to bind
the 5-HT3R antagonist [3H]granisetron. Table 2 shows the
Kd values for wildtype mouse 5-HT3ASRs and the 13
alanine mutations we evaluated. [3H]granisetron is a po-
tent antagonist of the wt 5-HT3R (Kd = 0.98 ± 0.12 nM).
This value agrees with published data for this compound
[19,20]. Bmax values range from the 5.5 pmoles/mg pro-
tein observed for E148A to 0.30 pmoles/mg protein for
the K153A mutation, indicating some variability in ex-
pression of the different receptors. In general, however, re-
ceptor expression was similar to that reported by other
laboratories [1,20–22]. No detectable binding was ob-
served for G147A and V149A mutant receptors. For all
other mutants, decreases in binding affinity (increased
Kd) were observed although the magnitude of the change
was less than 10 fold in all cases. A bar graph showing the
change in Kd value resulting from each alanine mutation
is shown in Figure 2A. The largest decreases in binding af-
finity were observed for Y142A (4.6 fold, Figure 3), E148A
(5.3 fold) and Q150A – K153A (6 – 8 fold).
Figure 1
5-HT3R ligands.
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Inhibition binding assays were also conducted. Four test
compounds with structures representative of the major
classes of 5-HT3R ligands were chosen: serotonin (5-HT,
the endogenous agonist), m-chlorophenylbiguanide
(mCPBG, agonist), d-tubocurarine (d-tc, antagonist) and
lerisetron (antagonist). The Ki values for inhibition of
[3H]granisetron binding by all four compounds are
shown in Table 3. Little change in Ki value was observed
for the majority of mutations. The values highlighted in
bold in Table 3 represent the Ki values for inhibition of
[3H]granisetron binding on mutant receptors that in-
creased over 10 fold compared to the Ki obtained for
wildtype receptors. The bar chart in Figure 2B illustrates
Figure 2
Changes in Ki or Kd (for binding of [3H]granisetron)
as a result of alanine mutations. The values shown are
the ratio of the Kd or Ki for wildtype and mutant receptors.
The length of each bar illustrates the magnitude of change in
either the Kd or Ki relative to wildtype while the direction
indicates an increase (up) or decrease (down) in the Kd or Ki.
A. Most alanine mutations produced little change in Kd. No
binding was detected for the G147A and V149A receptors
therefore no Kd could be determined. B. Changes in Ki were
small for most receptors although large changes were
observed for select ligands at Y140A, Y142A and Y152A
receptors. The relative increases in Ki for these amino acids
are as follows: 5-HT: Y140A 1.3 ± 0.30 fold, Y142A 110 ±
25 fold, Y152A 24 ± 5.6 fold mCPBG: Y140A 7.3 ± 1.7 fold,
Y142A 160 ± 36 fold, Y152A 24 ± 5.6 fold d-tc: Y140A 50 ±
12 fold, Y142A 6.5 ± 1.5, Y152A 10.0 ± 2.3 fold lerisetron:
Y140A 4.6 ± 1.1 fold, Y142A 160 ± 37 fold, Y152A 190 ± 43
fold
Figure 2: 
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Figure 3
Saturation binding isotherms for binding of
[3H]granisetron to wildtype, Y140A, Y142A and
Y152A receptors. The data shown represent the specific
binding of [3H]granisetron as determined from at least four
identical experiments. Specific binding was determined as the
fraction of total binding not inhibited by a saturating concen-
tration of mCPBG or MDL-72222. Data were combined and
fitted using non-linear curve fitting. Only small shifts in bind-
ing affinity to [3H]granisetron were observed on all three
mutants. Kd values, Bmax and Hill coefficients are shown in
Table 2.
Table 1: Sequence Comparison of Putative Binding Loop Region.
Primary amino acid sequence of representative members of the LGIC 
superfamily showing amino acid residues on either side of the con-
served glycine residue. The amino acids shown span the region from 
Y140 – P154 of the 5-HT3R. The conserved glycine is shown in bold. 
Amino acids identified in the binding site of other LGIC subunits and 
the tyrosines identified in this study are shown in red, bold italics [11–
17].
Figure 3: 
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the changes in Ki resulting from each mutation on the test
compounds. Ratios of Ki are shown as positive for increas-
es in Ki on mutant receptors versus wildtype and negative
for decreases. A positive change thus corresponds to a de-
crease in binding affinity for the compound as a result of
the mutation. Large decreases in binding affinity were ob-
served for select compounds only on the Y140A, Y142A
and Y152A mutations.
Table 2: [3H]Granisetron binding to wildtype and mutant 5-HT3ASRs.
Receptor Kd (nM) [3H]granisetron Bmax (pmol/mg protein) n
Wildtype 0.98 ± 0.12 3.2 ± .13 1 ± 0.12
Y140A 2.7 ± 0.19 0.44 ± .08 1.5 ± 0.14
V141A 2.5 ± 0.35 0.32 ± .04 1.3 ± 0.22
Y142A 4.5 ± 0.5 0.97 ± .14 1.6 ± 0.27
V143A 1.9 ± 0.28 1.1 ± .04 0.97 ± 0.13
H145A 1.3 ± 0.13 0.81 ± .07 1.38 ± 0.17
R146A 2.4 ± 0.34 1.0 ± .16 1.26 ± 0 .21
G 1 4 7 A ---
E148A 5.2 ± 1.2 5.5 ± 1.2 0.93 ± 0.19
V149A - - -
Q150A 6.3 ± 0.45 0.56 ± .09 1.19 ± 0 .1
N151A 6.9 ± 0.48 4.9 ± 1.1 1.66 ± 0.16
Y152A 7.8 ± 1.1 0.59 ± .10 1.4 ± 0.24
K153A 7.4 ± 0.61 0.30 ± .08 1.51 ± 0.17
The Kd, Bmax and Hill coefficient (n) were determined using non-linear curve fitting of binding data as described in the methods section. Each value 
represents the combined data from at least four experiments and is represented as ± SE. The Kd values were used to calculate the ratios plotted in 
Figure 2, indicating the change in binding affinity as a result of each individual mutation. A plot of the data obtained from Y140A, Y142A and Y152A 
is shown in Figure 3.
Table 3: Ki values for Inhibition of [3 H]granisetron binding to wildtype and mutant 5-HT3ASRs.
Ki (Inhibition of [3H]granisetron binding) nM
Receptor 5-HT (nM) MCPBG (nM) d-tc (nM) Lerisetron
Wildtype 74 ± 17 3.0 ± 0.55 6 ± 2.1 0.8 ± 0.19
Y140A 97 ± 20 22 ± 6.1 300 ± 120 2.1 ± 0.33
V141A 82 ± 9.2 4.1 ± 0.50 4.7 ± 0.87 0.20 ± 0.02
Y142A (8 ± 2.0) ×  103 470 ± 90 39 ± 19 130 ± 28
V143A 22 ± 2.2 2.0 ± 0.44 22 ± 2.6 1.5 ± 0.41
H145A 29 ± 6.5 0.60 ± 0.10 19 ± 2.6 0.42 ± 0.04
R146A 61 ± 14 15 ± 4.9 29 ± 4.9 2.3 ± 0.31
E148A 73 ± 11 8.2 ± 1.5 14 ± 1.7 2.8 ± 0.53
Q150A 170 ± 29 27 ± 3.9 9.3 ± 1.3 1.1 ± 0.21
N151A 140 ± 20 1.8 ± 0.18 9.3 ± 1.4 3.7 ± 0.62
Y152A (1.8 ± 0.4) ×  103 73 ± 26 60 ± 19 150 ± 36
K153A 270 ± 34 7.7 ± 2.0 17 ± 3.0 3.0 ± 0.66
IC50 values were determined from competition binding data using [3H]granisetron as described in the methods section. Ki values were calculated 
from the IC50 using the Cheng-Prusoff equation, the Kd value, and the concentration of [3H]granisetron (typically equal to the Kd). Each value rep-
resents the combined data from at least four experiments and is represented as Ki ± SE. Values in bold type indicate changes in Ki greater than or 
equal to 10 fold on mutant vs. wt receptors.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/15
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A more detailed analysis of the competition binding data
obtained for the Y140A, Y142A and Y152A mutations is
shown in Figure 4. For 5-HT, the Y142A mutation pro-
duced a 110 fold increase in Ki and Y152A produced a 24
fold increase. No change in Ki was observed for the Y140A
mutation (Figure 4A). The 5-HT3R agonistmCPBG
showed a similar profile for the changes in Ki values re-
sulting from mutations of the three tyrosines (Figure 4B).
As was observed for 5-HT, the Y142A mutation produced
a large increase in Ki (160 fold) while the Y14 0A and
Y152A mutations produced only 7 and 24 fold changes re-
spectively.
The Ki value for d-tc inhibition of [3H]granisetron binding
was altered only slightly by the Y142A or Y152A muta-
tions (6.5 fold and 10 fold changes respectively). The
Y140A mutation, however, produced a 50 fold increase in
the Ki compared to wildtype receptors (Figure 4C).
The Ki value for lerisetron inhibition of [3H]granisetron
binding was increased 160 fold by the Y142A mutation
and 190 fold by the Y152A mutation. Only a 4.6 fold
change in Ki resulted from the Y140A mutation. Leriset-
ron was the only compound for which a large increase in
the Ki was observed on the Y152A mutation (Figure 4D).
This mutation produced smaller changes in Ki for 5-HT
Figure 4
Inhibition of [3H]granisetron binding by 5-HT3R ligands. The data represent the combined results of at least four
experiments. Assays were conducted as described in Materials and Methods. Fractional response is the fraction of [3H]grani-
setron binding obtained in the presence and absence of inhibitor. An IC50 value was determined from the data using non-linear
curve fitting as described in the methods and the Ki value calculated using the Cheng-Prusoff equation, the Kd as determined in
Figure 3 and the concentration of ligand used to obtain the inhibition data. Kd values are reported in Table 3. A. 5-HT B.
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Figure 5
Whole cell patch clamp recording from tsA 201 cells transfected with wildtype and Y152A cDNA. Data were
obtained using whole cell patch clamp on tsA201 cells transfected with wt or Y152A mutant 5-HT3ASR cDNA. Cells were
clamped at a holding potential of -60 mV and 5-HT applied with a rapid perfusion system. The application time for 5-HT is indi-
cated by the bar above the curves. The responses indicated in A and B are representative examples of at least 4 sets of exper-
iments. A. Wildtype 5-HT3ASR. 5-HT was applied as indicated for a 4 s duration. The concentrations of 5-HT used and the
response amplitudes are: a. 0.3 µM (0.03 nA) b. 1.0 µM (0.96 nA) c. 3.0 µM (2.5 nA) d. 30.0 µM (4.4 nA), e. 100.0 µM (3.9 nA).
B. Y152A mutant receptors. 5-HT was applied as indicated for an 8 s duration. The curves in B were offset vertically for clarity.
The dashed line in each curve indicates the baseline level for that response. The concentrations of 5-HT used and the response
amplitudes are: f. 3.0 µM (0.10 nA) g. 100 µM (0.14 nA) h. 300.0 µM (0.57 nA) i. 1.0 mM (1.0 nA). C. Concentration response
curve for 5-HT activation of wt 5-HT3ASRs. Each data point represents the combined results of 4 experiments. Responses
were normalized to the response obtained at 30 µM and the curves fit as described in the methods section. EC50 = 2.7 ± 0.25
µM, n = 1.6 ± 0.22. D. Concentration response curve for 5-HT activation of Y152A 5-HT3ASRs. Each data point represents the
combined results of 4 experiments. The response did not plateau in the range of concentrations used and hence responses
were normalized to the maximum concentration of 5-HT (1 mM). The EC50 was estimated by fitting the data to the following
equation: I = Imax/(1 +(EC50/ [C])n), where is the normalized current at 5-HT concentration [C], EC50 is the concentration of
5-HT needed to obtain half maximal activation and n is the apparent Hill coefficient. Imax in this case represents the estimated
maximum current relative to the response obtained at 1 mM. To obtain the curve shown in the figure, the Hill coefficient was
fixed at the wt value of 1.6. The EC50 value obtained from this fit is 370 ± 27 µM.
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and mCPBG (24 fold for both) and only a 10 fold change
for d-tc.
In whole cell patch clamp studies, 5-HT perfusion of cells
transfected with Y140A and Y142A cDNA produced no re-
sponses at 5-HT concentrations of up to 1 mM although
specific binding to these receptors was identified in recep-
tor binding studies. Unlike Y140A and Y142A, Y152A re-
ceptors responded to application of 5-HT. Due to the low
potency of 5-HT on these receptors, only a portion of the
concentration response curve could be determined (up to
1 mM). The EC50 value was estimated as greater than 370
µM (Figure 5). This value shows a greater than 140 fold in-
crease in EC50 compared to wildtype receptors; a larger
change than was observed for the Ki (24 fold). The most
dramatic change observed for whole cell currents was an
alteration in the kinetics of the response elicited by appli-
cation of 5-HT. Y152A mutant receptors displayed much
slower rise times compared to wildtype receptors at all
concentrations tested. Peak wt responses were typically
obtained in less than 80 ms while Y152A responses re-
quired several seconds to plateau. Desensitization kinetics
were also altered. While wt receptors desensitized rapidly,
mutant receptors showed no desensitization during the 8
s perfusion time.
Discussion
The putative E-loop region of the LGIC family of receptors
is homologous to residues Y140 through K153 in the 5-
HT3R [4,12–18]. Structure-function studies of this region
have been conducted in several other members of this
family of receptors including GABAA and nAChR sub-
types. In each case, residues have been identified that alter
either the binding of selective ligands or receptor function
[4,11–18]. In order to determine if this loop also contains
residues critical to the structure or function of the 5-HT3R,
we have constructed alanine mutations of amino acids
throughout the homologous region of the mouse 5-
HT3ASR and investigated the affects on binding of 5 differ-
ent structural classes of 5-HT3R ligands. We have identi-
fied three tyrosine residues that appear to play a role in
binding of selective ligands to this receptor. In addition,
our data support the existence of a loop structure in this
region as has been hypothesized for the nAChR and iden-
tified in a homologous AChBP [12,23,24].
Representative members of 5 major structural classes of 5-
HT3R ligands were tested on all mutants (Figure 1). These
ligands include the antagonists [3H]granisetron, d-tc and
lerisetron, and the agonists 5-HT and mCPBG. Most of the
mutations tested produced only minor changes in bind-
ing affinity for these ligands. Large changes in binding are
only apparent on Y140A, Y142A and Y152A receptors for
select ligands. The resulting effects of individual muta-
tions are specific to particular structural classes of ligands.
The Y140A mutation altered the Ki for d-tc inhibition, but
did not alter the Ki obtained for any other compound test-
ed, while Y142A altered the Ki for mCPBG, 5-HT and leri-
setron but had little if any effect on inhibition by d-tc.
These data indicate the highly specific nature of the effects
introduced by the alanine mutations and appear to reflect
specific changes in ligand/receptor interaction.
Binding of [3H]granisetron is altered only slightly by the
alanine mutations introduced in this study (<10 fold).
This result indicates the lack of involvement of amino ac-
ids in this binding loop in the binding of [3H]granisetron.
It is apparent, however, that [3H]granisetron does occupy
the same binding cleft as other 5-HT3R ligands as evi-
denced by the ability of 5-HT, mCPBG, d-tc and lerisetron
to displace it from the binding site. The lack of any large
change in binding of granisetron supports our contention
that there is little global structural perturbation of the
binding site resulting from the introduction of each indi-
vidual alanine mutation.
The Ki for inhibition of [3H]granisetron binding by 5-HT
was increased 110 fold by the Y142A mutation. A similar
increase was also observed for mCPBG (160 fold). In con-
trast, the Y140A and Y152A mutations produced relatively
small changes in the Ki. Since both compounds are 5-
HT3R agonists, they are likely to share the same binding
interactions. One of these interactions appears to be with
Y142. Other studies have also identified binding site inter-
actions for agonists. R91, E106, F107, W183 and several
residues adjacent to the M1 region have all been demon-
strated to alter the action of 5-HT and/or mCPBG
[20,21,25,26]. Within the crystal structure of the AChBP,
homologous residues are located in the apparent binding
site [24]. The effects of agonist on the 5-HT3R are mediat-
ed by their interaction with these binding site residues, re-
sulting in stable receptor conformations, including the
channel open state. Identification of interacting amino ac-
ids and their location in the tertiary structure of the recep-
tor may provide clues to the mechanism of channel
opening. For example, amino acids homologous to Y142
and W183 (R104 and W143 respectively) are in close
proximity in the AChBP, although on complementary fac-
es of the receptor subunits [24]. Spier et. al. have suggested
that W183 may be involved in a cation-π  interaction with
the amino group of 5-HT and mCPBG [26]. If W183 and
Y142 are located near each other but on opposite faces of
the binding site in the 5-HT3R, then they could potentially
act in concert to help stabilize a conformation of the re-
ceptor leading to channel opening.
d-Tubocurarine inhibition was uniquely altered by the
Y140A mutation. An increase in Ki of 50 fold was ob-
served for d-tc on this mutant. Little if any change resulted
for any other mutation. Thus, while d-tc may form an in-BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/15
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teraction with the receptor at this binding loop, it appears
to interact with Y140 rather than Y142 or Y152. This dif-
ference in binding site interactions of the antagonist d-tc
and the agonists 5-HT and mCPBG could be the result of
a slightly different positioning of d-tc in the binding site.
The antagonists d-tc and [3H]granisetron also interact dif-
ferently with this region since [3H]granisetron binding
was not altered by mutations at any of the amino acids
tested. While the binding of d-tc appears to involve some
interaction with this binding loop, the binding of
[3H]granisetron does not. Previous studies have indicated
a point of overlap between [3H]granisetron and d-tc at
W89 of the 5-HT3ASR. [20]. These studies indicate that the
binding regions for these antagonists are partially overlap-
ping at W89 but not at Y140. In addition to Y140 and
W89, d-tc has also been observed to interact with D206
and several other residues in loop C [27]. The d-tc binding
site appears to involve interaction with at least three dif-
ferent binding loops (A, E and C) although additional in-
teracting amino acids may be found. Data obtained for d-
tc is particularly valuable due to the rigid nature of this
molecule. Determination of interacting functional groups
and their relationship to individual amino acids could en-
able d-tc to be used as a molecular ruler to determine rel-
ative positions of these amino acids.
Lerisetron inhibition of [3H]granisetron binding to mu-
tant receptors was also investigated. Lerisetron is a potent
5-HT3R antagonist first synthesized by Orales et. al.[28].
As was observed for 5-HT3R agonists, lerisetron binding
was altered by the Y142A mutation. This mutation pro-
duced an increase in the Ki of 160 fold compared to
wildtype receptors. This increase in Ki indicates an impor-
tant interaction of lerisetron with Y142 and a similarity
between the binding location of lerisetron, 5-HT and
mCPBG. Lerisetron is the only antagonist tested that
shares a binding site interaction in this region with ago-
nists. In contrast to 5-HT and mCPBG, however, lerisetron
also interacts with Y152 as indicated by the 190 fold in-
crease in Ki on Y152A mutant receptors. Since neither d-tc
nor [3H]granisetron interacts with Y142 or Y152, there ap-
pears to be a difference between the interactions formed
by these antagonists compared to lerisetron. The binding
sites of the three antagonists tested differ with respect to
this binding loop. Since the role of a competitive antago-
nist is simply to block the binding of agonists and prevent
channel opening, the specific amino acids that interact
with the ligand can vary for different antagonists. This is
less likely to be the case with agonists since they must pro-
duce a conformational change in the protein to exert their
effects.
Only two mutant receptors failed to bind [3H]granisetron;
G147A and V149A. G147 is the conserved glycine in this
putative binding loop. Chirara et. al. have suggested that
the highly conserved nature of the glycine in this region
may indicate the existence of a loop structure consisting of
either γ  or a loose three residue-turn in the nAChR [12].
Either of these turns would bring the two putative β -
strands together such that γ L109, γ Y111 and γ S115 and
γ Y117 are all on the same side of an antiparallel β -sheet.
These residues have been identified by affinity labeling,
site-directed mutagenesis or cysteine substitution to lie on
the same surface. A classic 2-residue β -turn would place
these residues on opposite surfaces [12]. Substitution of
the conserved glycine by alanine may disrupt the structure
of this region and prevent assembly or expression of the
receptor. The recent determination of the crystal structure
of an AChBP supports this hypothesis. The AChBP dis-
plays a large amount of homology to the amino terminal
of LGIC receptors and thus may be similar in structure
[20,24]. The crystal structure of this protein reveals a loose
3 residue turn incorporating the conserved glycine residue
[24]. Homologous residues in other LGIC subunits have
also been identified and are shown in Figure 1. The resi-
dues identified in this study as altering binding affinity of
5-HT3R ligands would also be present on the same surface
if this structure is present in the 5-HT3R. While Y140 lies
somewhat outside the region identified by Chiara in the
nAChR (homologous to γ N107), γ L109 and γ L119 are ho-
mologous to Y142 and Y152 of the 5-HT3ASR. The ability
of lerisetron to interact with both Y142 and Y152 also
supports the hypothesis that these two amino acids are
present in a loop structure since the eight intervening res-
idues would position Y142 and Y152 too far apart to per-
mit them both to interact with a single ligand even if they
were interacting with functional groups on opposite ends
of the molecule. A loop structure would bring them into
closer proximity and permit interaction with the small
molecule lerisetron.
All three tyrosine mutations were investigated using a
whole cell patch clamp assay to determine if functional
changes could be observed. Whole cell responses could
not be obtained for Y140A or Y142A, although specific
binding of [3H]granisetron was observed. These data sug-
gest that, while the receptors do assemble and are capable
of binding [3H]granisetron, they are either not transport-
ed to the cell surface or are non-responsive to 5-HT at con-
centrations of 1 mM or less.
Y152A does produce functional channels however they
display distinctly altered response kinetics when com-
pared to wildtype receptors. Y152A responses do not
show the rapid rise times observed in wt receptors. The ex-
tremely slow rise times observed for Y152A receptors may
indicate a change in rate constants preceding channel
opening. These changes in the rate constants for either ag-
onist binding or channel opening also produce a 140 fold
decrease in the observed EC50 for 5-HT activation. TheBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/15
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slow rise is followed by a non-desensitizing phase of the
response that is dramatically different from the fast desen-
sitization observed for wt 5-HT3ASRs. Lack of desensitiza-
tion could result from either a stabilization of the open
state of the channel or a destabilization of the desensi-
tized state. Mutations of homologous or nearby residues
in both the nAChR and GABAA receptors have also been
demonstrated to alter the agonist response. Mutation of
the homologous residue in the GABAA receptor γ -subunit
(T142) to serine altered the efficacy of the agonist Fluma-
zenil, converting it to a partial agonist [29]. In the nAChR,
mutation of mouse and rat ε P121 to leucine altered both
the binding of acetylcholine and the stability of the open
state of the channel. ε P121 is homologous to P154 in the
5-HT3R and is only two residues away from Y152. The au-
thors of this study concluded that this portion of the ace-
tylcholine binding site was closely linked to the channel
opening region of the receptor [30]. It is reasonable to
conclude that the homologous region in the 5-HT3R may
perform a similar function. The link between an agonist
binding domain and a conformational change leading to
channel opening is not unexpected since the two must ob-
viously be linked. If binding to this region of the receptor
is shown to be a critical step between the binding of ago-
nists and the opening of the channel, further investigation
of the amino acids in this loop may provide valuable clues
to molecular basis of this process.
Conclusions
Our data indicate an important role for this putative bind-
ing site loop in the interaction of the 5-HT3R with differ-
ent ligands and illustrate the difference in binding of
different structural classes of ligands. Each structural class
shows different patterns of interaction with amino acids
in this region of the receptor. [3H]granisetron does not ap-
pear to interact with any of the amino acids tested while
d-tc interacts with only Y140, mCPBG and 5-HT with Y142
and lerisetron with both Y142 and Y152. Similar selective
effects have been observed on other residues including
W183, W89, F107 and E106 among others[20,21,25,26].
Our data in conjunction with those of other laboratories
indicates the differences in orientation of different ligands
within the same binding cleft. These differences in orien-
tation result in different amino acid/functional group in-
teractions. As the structural detail of these interactions
emerges, these differences could potentially be exploited
to produce more potent and specific ligands. For example
construction of a "hybrid" ligand that combines the inter-
actions of [3H]granisetron with those of d-tc, 5-HT or
mCPBG could produce an antagonist with increased affin-
ity due to the additional binding energy of these interac-
tions and a greater specificity since it would utilize more
structural features of the binding site.
The requirement of a glycine at position 147 and the abil-
ity of lerisetron to interact with both Y142 and Y152 also
support the hypothesis that the secondary structure in this
region of the receptor is formed by a loop structure. If the
loose 3 residue turn proposed by Chiara et. al. and shown
for the AChBP is present in the 5-HT3R, then Y140, Y142
and Y152 would be present on the same side of the sheet
and all three would be capable of extending into the bind-
ing site. A similar observation has been made for the
nAChR where γ S111, γ Y117, γ L119, δ R113 and δ T119 of
the mouse nAChR receptor and γ L109 and γ Y111 of the
torpedo nAChR are all thought to be present in the bind-
ing site [12–18].
Materials and Methods
Materials
[3H]granisetron was purchased from New England Nucle-
ar, 5-HT from Spectrum, and mCPBG and d-tc from Re-
search Biochemical International. Lerisetron was
provided by Dr. Karen Kirschbaum at The University of
Louisiana at Monroe, Monroe, LA. All other reagents were
obtained from commercial sources.
Site directed mutagenesis
Wild type 5-HT3AS mouse receptor cDNA was obtained
from Dr. Michael White [20]. Mutant receptors were con-
structed using either the Quick Change Mutagenesis kit
(Stratagene) or the Altered Sites Mutagenesis kit (Prome-
ga). All mutations were confirmed by commercial DNA
sequencing.
Cell culture and transfection
tsA201 cells, a derivative of HEK293 cells, were seeded at
a density of 5 ×  106 cells/100 mm dish. Cells were grown
in DMEM medium containing 10% FBS, 100 units/ml
penicillin/streptomycin for nine hours in 5% CO2 and
transfected with 10 µg mouse 5-HT3ASR cDNA per 100
mm dish using the calcium phosphate technique (New
Life Technologies, NY). Media was changed 12–14 hrs af-
ter transfection. The cells were allowed to grow for anoth-
er 24 hours and then harvested.
For whole cell patch clamp experiments, tsA201 cells were
seeded to a density of 0.25 ×  106 cells/60 mm dish. Cells
were grown in DMEM culture medium containing 10%
FBS and 100 units/ml penicillin/streptomycin for 12
hours prior to transfection. Transfections were performed
using Superfect Transfection Reagent (Qiagen, CA). Ten
µg of cDNA were mixed with DMEM medium containing
no serum or antibiotics in a volume of 150 µl. Twenty µl
of Superfect reagent were then added and the mixture in-
cubated at room temperature for 15 min. The reaction was
terminated by adding 1 ml of DMEM medium containing
10% FBS and 100 units/ml penicillin/streptomycin and
the entire mixture added to cells in the 60 mm dish. CellsBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/15
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were exposed to Superfect Reagent for 3 hours. At that
time, the reagent was replaced with DMEM medium con-
taining 10% FBS and 100 units/ml penicillin/streptomy-
cin and incubated for an additional 24 hours prior to use.
Binding assays
Transfected cells were scraped from the dishes, washed
twice with Dulbecco's PBS (New Life Technologies, NY),
then resuspended in 1.0 ml ice cold PBS/100 mm dish.
Cells were either used fresh or frozen at this step until
needed. Immediately prior to use, cells were homoge-
nized on ice in PBS using a glass tissue homogenizer then
centrifuged at 35 000 ×  g for 30 minutes in a Beckman
JA20 rotor (4°C). Membranes were washed once more
with PBS at 4°C then resuspended in 1 ml PBS/100 mm
dish. Protein content was determined using a Lowry assay
(Sigma. Diagnostics, St. Louis, MO). Membranes were in-
itially prepared and Bmax and Kd values determined in the
presence and absence of a cocktail of protease inhibitors
(Complete Protease Inhibitor Cocktail, Roche Diagnos-
tics, Mannheim Germany). No change in Bmax was ob-
served as a result of omitting the protease inhibitor (Bmax
(+ protease inhibitor)= 3.1 ± 0.11 pmoles/mg protein vs
Bmax (- protease inhibitor) = 3.2 ± 0.13 pmoles/mg pro-
tein.) hence all assays were performed in the absence of
the cocktail. Binding assays were performed in PBS.
For Kd determinations, 100 µl of homogenate was incu-
bated at 37°C for 1 hour with varying concentrations of
[3H]granisetron (NEN, MA). Specific binding of [3H]gran-
isetron was determined as the bound [3H]granisetron not
displaced by a saturating concentration of a competing
ligand. Kd values were determined by fitting the binding
data to the following equation using Graphpad PRISM
(San Diego CA): B = Bmax [L]n / ([L]n + Kn), where B is
bound ligand, Bmax is the maximum binding at equilibri-
um L is the free ligand concentration and n is the Hill co-
efficient.
Ki determinations, 100 µl of homogenate was incubated
at 37°C for 2 hours with varying concentrations of inhib-
itor and [3H]granisetron (NEN, MA). Binding was termi-
nated by rapid filtration onto a GF/B filters. The IC50
values were calculated by fitting the data to the following
equation using Graphpad PRISM (San Diego CA): θ  = 1/
(1+(L/IC50)), where θ  is the fractional amount of
[3H]granisetron bound in the presence of inhibitor at con-
centration L as compared to the amount of [3H]graniset-
ron bound in the absence of inhibitor. IC50 is the
concentration at which θ  = 0.5. The Ki is calculated from
the IC50 value using the Cheng-Prusoff equation.
Electrophysiological Recordings
Transfected cells were transferred to a recording chamber
containing extracellular solution (140 mM NaCl, 1.7 mM
MgCl2, 5 mM KCl, 1.8 mM CaCl2, 25 mM HEPES pH 7.4).
Patch electrodes of resistance 2.5–3.0 MΩ  were filled with
filtered intracellular solution containing 145 mM KCl, 2
mM MgCl2, 1 mM EGTA, 25 mM HEPES (pH 7.4). Cells
were clamped in whole cell configuration at a holding po-
tential of -60 mV. A continuous extracellular solution flow
(0.8 ml/min) was maintained throughout the recording
procedure. 5-HT was dissolved in extracellular solution
and delivered to cells using a rapid perfusion system
(Warner Instruments, Hamden, CT) at a rate matching the
extracellular solution flow rate. The drug perfusions lasted
for a period varying from 4 to 8 seconds. Currents elicited
by agonist application were measured using an Axopatch
200 B amplifier (Foster City, CA). The data were plotted
and analyzed by non-linear curve fitting (Graphpad
PRISM, San Diego CA) according to the following equa-
tion: I = 1/(1 +(EC50/ [C])n), where is the normalized cur-
rent at 5-HT concentration [C], EC50 is the concentration
of 5-HT needed to obtain half maximal activation and n is
the apparent Hill coefficient.
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